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Abstract
Trypanosoma cruzi calreticulin (TcCRT) is a virulence factor that binds complement C1, thus inhibiting the activation of the
classical complement pathway and generating pro-phagocytic signals that increase parasite infectivity. In a previous work,
we characterized a clonal cell line lacking one TcCRT allele (TcCRT+/2) and another overexpressing it (TcCRT+), both derived
from the attenuated TCC T. cruzi strain. The TcCRT+/2 mutant was highly susceptible to killing by the complement
machinery and presented a remarkable reduced propagation and differentiation rate both in vitro and in vivo. In this report,
we have extended these studies to assess, in a mouse model of disease, the virulence, immunogenicity and safety of the
mutant as an experimental vaccine. Balb/c mice were inoculated with TcCRT+/2 parasites and followed-up during a 6-
month period. Mutant parasites were not detected by sensitive techniques, even after mice immune suppression. Total anti-
T. cruzi IgG levels were undetectable in TcCRT+/2 inoculated mice and the genetic alteration was stable after long-term
infection and it did not revert back to wild type form. Most importantly, immunization with TcCRT+/2 parasites induces a
highly protective response after challenge with a virulent T. cruzi strain, as evidenced by lower parasite density, mortality,
spleen index and tissue inflammatory response. TcCRT+/2 clones are restricted in two important properties conferred by
TcCRT and indirectly by C1q: their ability to evade the host immune response and their virulence. Therefore, deletion of one
copy of the TcCRT gene in the attenuated TCC strain generated a safe and irreversibly gene-deleted live attenuated parasite
with high immunoprotective properties. Our results also contribute to endorse the important role of TcCRT as a T. cruzi
virulence factor.
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Introduction
Chagas disease is a neglected tropical ailment caused by the
flagellate protozoan Trypanosoma cruzi. It is estimated that 12–20
million people are infected worldwide causing 10–50,000 deaths/
year [1]. Vector control strategies were not entirely successful
mainly due to the inaccessibility and the vast distances that
separate endemic areas. Transmission, despite the spraying of
insecticides, has been increasing in parts of Argentina, Venezuela
and Brazil [2]. In addition, the cases of Chagas disease have raised
in many parts of South America and have spread globally because
of immigration into non-endemic areas in developed countries
[3,4,5]. Drugs used for treatment have serious adverse effects and
do not cure the chronic stage [6]. However, vaccination to protect
the 40–100 million individuals at risk of acquiring this serious
disease has not been well developed or entered in human trials.
Considering T. cruzi complexity, with a genome of more than
12,000 genes and four distinct life stages, DNA and peptide
vaccination for Chagas disease is insufficient and has, so far, not
been reported to induce sterile immunity after challenge [7].
Currently, there is an increased interest in the development of
irreversibly gene-deleted live attenuated parasites, as a possible
mechanism to reduce the risk of reversion to virulence. There is
considerable evidence in genetically modified organisms such as
Toxoplasma, Plasmodium and Leishmania, which argues for the
usefulness and effectiveness of these parasites as promising
immunogens [8,9,10,11,12,13,14,15,16]. In T. cruzi, unfortunate-
ly, there are so far only five studies of vaccination using genetically
attenuated strains [17,18,19,20,21]. The advantages of using this
kind of immunogens are: (1) They can provide the full spectrum of
relevant native epitopes and immune stimulating molecules, such
as Toll-like receptors organized together, which would generate a
high immunogenicity, unlike other types of vaccines that offer only
a restricted spectrum of immunogens. (2) They can be manipu-
lated to develop multiple genetic modifications. (3) They undergo
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antigen processing and presentation as in the case of virulent
infection. (4) They generate, after inoculation, a strong and long
lasting protective response compared with other experimental T.
cruzi vaccines [7]. (5) They can be grown in axenic conditions with
a lower economic production cost than other vaccine strategies
[22].
The TCC wild type strain does not produce considerable tissue
lesions or bloodstream parasite levels detectable by fresh blood
mounts in rats [23]. Immunization with TCC provided, after a
virulent challenge, a strong immune protection against virulent T.
cruzi infections [24,25], also evidenced when the challenge was
performed using 17 isolates of T. cruzi obtained in an extensive
endemic area of the Province of Salta, Argentina [26]. A strong
control of parasitemia and tissue damage was observed in mice
challenged a year after immunization [27,28]. The protective
effect of TCC was extended to field experiments in guinea pigs
[25] and dogs [29]. Unfortunately, the TCC attenuation is
genetically undefined and the possibility of reversion to the
virulent phenotype cannot be excluded. In order to add a safety
mechanism to prevent this reversion, in a previous work, we
generated and characterized a TCC clonal cell line that lacks a
TcCRT allele (TcCRT+/–) and another clone overexpressing it
(TcCRT+). TcCRT is a T. cruzi virulence factor, that after being
translocated from the endoplasmic reticulum (ER) to the area of
flagellum emergence, can hijack the complement C1 component,
inhibiting the activation of the classical and lectin complement
pathways at their earliest stages [30,31,32] and producing pro-
phagocytic signals increasing parasite infectivity [33]. Recently, an
important role of TcCRT in the C1-dependent T. cruzi infectivity
of human placenta explants has been determined in one of our
laboratories, thus providing a plausible mechanism for congenital
transmission of this infection [34]. In our previous work, we
determined that the TcCRT+/– mutant contained about 6-fold
less TcCRT polypeptide than wild type parasites [35]. Moreover,
parasites overexpressing TcCRT contained about 2-fold more
TcCRT polypeptide than wild type parasites. Consequently,
monoallelic mutant parasites were significantly more susceptible to
killing by the complement machinery. On the contrary, TcCRT+
parasites showed higher levels of resistance to killing by the
classical and lectin but not by the alternative complement
activation pathways. The involvement of surface TcCRT in
depleting C1 was confirmed through restoration of serum killing
activity by addition of exogenous C1. In axenic cultures, a reduced
propagation rate of TcCRT+/– parasites was observed. More-
over, TcCRT+/– parasites presented a reduced rate of differen-
tiation in in vitro and in vivo assays [35].
The previous studies led us to the objective of this report, to
detect whether the TcCRT monoallelic deletion caused changes in
the infectivity and immunoprotective behavior of the attenuated
TCC strain.
Materials and Methods
Ethics statement
All animal protocols adhered to the National Institutes of
Health (NIH) ‘‘Guide for the care and use of laboratory animals’’
and were approved by the Animal Ethics Committee of the School
of Health Sciences, National University of Salta (Nu 014-2011)
[36].
Trypanosomes cultures
A T. cruzi clone derived from the attenuated TCC strain [37],
designated here as wild type, was used. Also, we used a clonal cell
line lacking one TcCRT allele (TcCRT+/2) and a recombinant
T. cruzi clone that overexpresses the TcCRT polypeptide
(TcCRT+) [35]. Epimastigotes were grown at 28uC in liver
infusion-tryptose medium (LIT) supplemented with 10% fetal
bovine serum decomplemented at 56uC for 60 min., 20 mg hemin
(Sigma, St. Louis, MO, USA),100 IU of penicillin and 100 mg/ml
streptomycin. To obtain metacyclic trypomastigotes, epimastigote
forms were allowed to differentiate by adding 10% w/v triatomine
gut homogenate to the cultures [38]. The percentage of metacyclic
forms was recorded daily in a Neubauer chamber. In addition, we
used the Tulahue´n strain and a highly infective isolate recently
characterized [39].
Hemocultures and PCR
Hemocultures were performed by seeding 200 ml of heparinized
blood into 2 ml of LIT under sterile conditions; the cultures were
incubated at 28uC and scanned for motile parasites under an
inverted microscope on days 15, 30, 45, and 60. PCR for T. cruzi
detection was also performed. Briefly, 700 ml of blood from each
inoculated animal was processed. Kinetoplast DNA was amplified
using primers 121 (59-AAATAATGTACGGGTGAGATGCAT-
GA-39) and 122 (59-GTTCGATTGGGGTTGGTGTAATATA-
39). Sample storage, DNA extraction, amplification, electrophore-
sis and staining were performed as previously described [40].
Mutation stability
To assess the stability of the mutation, we used TcCRT+/– and
TCC wild type parasites recovered from hemocultures performed
on nude mice on day 90 post-infection (p.i.) after immunosup-
pression with cyclophosphamide. These parasites were grown and
expanded in LIT medium. Genomic DNA was purified using the
phenol–chloroform method. Diagnostic PCR analysis confirmed
sequences corresponding to TcCRT and HYG gene. Primers used
were: Pair 1, to amplify the entire TcCRT CDS (1.2 Kb), CRT1
(5’-GCCAGATATCATGAGGAGAAATGACATAAA-3’) which
anneals into the TcCRT initiation codon and CRT2 (5’-TCC-
TCTCGAGTCAAAACTTTCCCCACCGAA-3’), for the stop
Author Summary
Trypanosoma cruzi is a protozoan parasite which infects 9
million people in Latin America. Currently there is no
vaccine to prevent this disease. Therefore, different
approaches or alternatives are urgently needed to identify
new protective immunogens. Live vaccines are likely to be
most effective in inducing protection; however, safety
issues associated with their use have been raised. Hence,
we genetically manipulated an attenuated strain of T. cruzi
as a safety device to rule out the possibility of reversion to
the virulent phenotype. The genetically modified parasites
were highly susceptible to killing by the complement
machinery and presented a reduced propagation and
differentiation rate. We have extended these studies to
assess, the virulence, immunogenicity and safety of the
mutant as an experimental vaccine. Accordingly, we show
that genetically modified parasites present attenuated
virulence in mice. The genetic alteration was stable and,
after long term infection, it did not revert back to wild type
form. Furthermore, after challenge with a virulent T. cruzi
strain, mutant immunization induces a highly protective
response evidenced by significantly lowered parasite
density, mortality, spleen weight index and tissue inflam-
matory response. Our study provides new insights into the
host-pathogen interactions and into the use and evalua-
tion of irreversibly gene-deleted live attenuated parasites
to protect against Chagas disease.
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codon. Pair 2, to amplify the CDS of HYG gene (0.96 kb), H1 (5’-
CGTCTGTCGAGAAGTTTCTG-3’) which anneals into the
HYG initiation codon and H2 (5’-GAAGTACTCGCCGATAG-
TG-3’) for the stop codon. Pair 3, CRT 7 (5’-CCTTCCGATGG-
CATTAGC-3’) which anneals upstream of TcCRT gene plus
primer H4 (5’-CTCGCTCCAGTCAATGACC-3’) for the HYG
sequence (1.4 kb). Pair 4, CRT93 (5’-ATTCCAAACAACATTG-
CCGT-3’) which anneals downstream of TcCRT gene plus H6
(5’-GGACCGATGGCTGTGTAGAAGTACTCGCCGATAG-
TGG-3’) for the HYG sequence (1.4 kb).
Serological determinations
Total Immunoglobulin G antibodies against T. cruzi were
measured by Enzyme-linked Immunosorbent Assay (ELISA) using
T. cruzi epimastigote homogenates (2 mg/well) as antigens.
Dilutions of sera, anti-mouse IgG as a secondary antibody (Sigma,
St. Louis, MO, USA) and conjugate were 1/100; 1/2,500 and 1/
16,000 respectively. The antibody concentration was expressed as
the optical density at 490-nm wavelength.
In vivo infectivity assays
Male Balb/c inbred or athymic nude (nu/nu) immunodeficient
mice (about 1 month old) were inoculated intra-peritoneally (i.p.)
with 56105 metacyclic TCC TcCRT+/–; TcCRT+ and wild type
trypomastigotes. Balb/c mice were subjected to PCR (15, 30, 90,
180 and 220 days p.i.), hemoculture (15, 30, 90 and 220 days p.i.)
and serological determination of antibody levels (20, 47, 60, 90
and 165 days p.i.) as described above. Nude mice were examined
by PCR and hemoculture on day 15, 30 and 90 p.i. To improve
the detection of latent infections, the last sample of both, Balb/c
and nude mice, were obtained after immunosuppressive treatment
with cyclophosphamide. The immunosuppression regimen is
based on 5, 250 mg/kg cyclophosphamide doses administered
during 10 days. Samples were collected 10 days after the last dose.
Immunization assays
To test whether mutant T. cruzi clones induced immunological
protection, groups of 6 Balb/c mice, about 1 month old, were
inoculated i.p. with 56105 metacyclic TCC TcCRT+/–;
TcCRT+ and wild type trypomastigotes. A control group was
inoculated with 100 ml of PBS (day 0). On day 15 a boost similar to
the initial inoculation was administered. On day 30, antibody
levels from immunized mice were determined and, on day 120, all
groups were challenged with 104 blood trypomastigotes of a highly
virulent T. cruzi TcVI isolate, recently characterized [39]. Blood
was drawn from the tail tip of mice, under slight ether anesthesia
using heparinized, calibrated capillary tubes. Ten microliters of
blood were placed between slide and cover slip and the number of
parasites per 100 fields was recorded microscopically (40X) twice a
week. Then, the number of parasites per 100 fields (parasitemia)
was recorded from fresh blood mounts under microscope (40X).
Finally, on day 60 post-challenge, surviving animals were
sacrificed, spleen index and the presence of histological damage
was measured in tissue samples.
Histopathology
Tissue samples from heart and quadriceps muscle were fixed in
10% formaldehyde and processed using routine histological
techniques. Serial histological hematoxylin-eosin-stained sections
(3–5 mm thick) were studied. We searched for lymphocytic
infiltrates in areas averaging 53 mm2 for heart and 38 mm2 for
quadriceps muscle, scanning at least three sections per organ.
Quantification of the inflammatory response was scored blindly as
severe (+++: presence of foci containing numerous inflammatory
cells covering at least half of the sections surface), moderate (++:
large inflammatory foci covering up to J of the section surface),
slight (+: presence of small and isolated inflammatory foci) or
absent (–: no presence of foci or inflammatory cells).
Spleen index
Body and spleen weight were determined to calculate the spleen
index (spleen index = spleen weight X 100/body weight) as an
indirect effect of infection severity.
Statistical analysis
The Mann-Whitney U tests and one-way variance analysis
(ANOVA) of the GraphPad Prism version 5.0 software were used.
Values are expressed as means 6 standard error of mean of at
least three separate experiments. P values equal to or minor that
0.05 were considered as significant.
Results
TcCRT+/– parasites showed attenuated virulence
To determine whether the TCC mutant parasites were capable
of infecting and survive for long periods of time in the host, we
monitored their in vivo infectivity and persistence. TCC
TcCRT+/–; TcCRT+ and wild type epimastigotes were trans-
formed into metacyclic trypomastigotes and inoculated (56105) in
Balb/c and nude mice. Since the T. cruzi TCC strain is attenuated
it is not possible to detect circulating parasites in blood samples by
fresh blood mounts. Therefore, infection was detected by more
sensitive methods (hemoculture and PCR). No positive hemocul-
tures were obtained from any immunocompetent Balb/c mice
inoculated with the three clones at any of the evaluated time points
(Table 1). However, PCR determinations showed different
infection patterns. No positive PCR was detected in TcCRT+/–
immunocompetent inoculated mice throughout the follow-up,
beyond 200 days, and even after immunosuppression. In contrast,
positive reactions were found in all animals infected with wild type
parasites. After immunosuppression, 2/3 of wild type inoculated
mice were positive. All mice infected with TcCRT+ parasites
presented a behavior similar to the wild type strain (Table 1).
Thus, the attenuated TCC T. cruzi strain could be rendered even
less virulent than wild type via the targeted deletion of one TcCRT
allele.
Using nude mice we detected an increased rate of infection by
PCR and hemoculture in all three experimental groups. No
differences were found between the strains at any time p.i. As
expected, after immunosuppression we detected a high mortality
in all groups (Table 1).
Infection with TcCRT+/– parasites induces lower levels of
anti-T. cruzi antibodies
We determined serum antibody levels in BALB/c mice infected
with the three parasite clones on acute and chronic stages of
infection and disease developmenRTt. TcC+/– infected mice
showed undetectable antibody levels (p = 0.01) contrasting with
mice inoculated with both wild type and TcCRT+ parasites. In
fact, the TcCRT+/– values were comparable to those obtained
from the PBS-inoculated, negative controls. No differences
between TcCRT+ and wild type were found (p = 0.84). As
previously described [27], mice inoculated with the Tulahue´n
virulent strain (positive control) showed about six-fold higher
antibody levels than those obtained with any of the TCC strains
(Fig. 1).
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The TcCRT+/– mutation remains stable during chronic
infection in mice
To exclude the possibilities of cross-contamination, reversion of
the genetic mutation or TcCRT locus instability, we determined
whether the parasites isolated from hemocultures after long term
infection in mice corresponded to mutant parasites. Genomic
DNA was extracted from TcCRT+/– and wild type parasites
grown on hemocultures at day 90 p.i. (Table 1). We amplified
sequences corresponding to the TcCRT coding sequence (CDS)
and the hygromycin phosphotransferase (HYG) marker gene. The
sizes of amplified fragments in the DNA of the recovered parasites
corresponded to those predicted for the replacement of TcCRT by
the HYG gene (Fig. 2).
Additionally, the antibiotic resistance of TcCRT+/– and wild
type parasites were tested. Only TcCRT+/– parasites survived in
the presence of 300 mg/ml Hygromicin B mediated by the HYG
resistance gene at the deleted TcCRT allele (data not shown).
Thus, this evidence showed that TcCRT+/– parasites conserved
the targeted allele introduced by homologous recombination, that
there is no cross-contamination and that the locus remained stable
throughout the infection cycle in the mammalian host.
Infection with TcCRT+/– parasites induces protective
immunity
To assess the immunoprotective capacity of mutant parasites
against a subsequent reinfection with virulent parasites, groups of
six BALB/c mice were inoculated with 56105 metacyclic
trypomastigotes of each of the three clones plus a naive, sham-
preinoculated control group. At day 15 a booster similar to the
initial inoculation was administered. To determine whether this
immunization regimen induces an immune response, blood
samples were taken during the immunization phase on day 30
post-priming. After 120 days, these mice together with controls
were challenged with 10,000 bloodstream trypomastigotes of a
virulent T. cruzi isolate [39]. The protective response generated by
immunizing with TcCRT+/– and wild type was significantly
Table 1. Infectivity and persistence of TcCRT mutants in Balb/c and nude mice.
(Positive mice)/(total mice studied)
PCR Hemoculture
Mouse strain T. cruzi clone 15 30 90 180 220 15 30 90 220
Balb/c TcCRT+/– 0/5 0/5 0/5 0/4 0/3* 0/5 0/5 0/4 0/3*
wild type 5/5 5/5 5/5 5/5 2/3* 0/5 0/5 ND 0/2*
TcCRT+ 4/5 5/5 4/4 4/4 2/2* 0/5 0/5 ND 0/2*
Nude TcCRT+/– 3/4 4/4 0/1* ND ND 4/4 3/4 1/1* ND
wild type 5/6 3/4 1/1* ND ND 5/6 4/4 1/1* ND
TcCRT+ 4/6 4/5 1/2* ND ND 4/6 4/5 0/2* ND
Infectivity in mice infected with 56105 metacyclic TcCRT+/–, wild type and TcCRT+ trypomastigote clones in Balb/c and nude mice, as detected by hemoculture and
PCR. ND= not done. Numbers in the third line refer to days p.i. (*) samples obtained after cyclophosphamide immunosuppression.
doi:10.1371/journal.pntd.0002696.t001
Figure 1. TcCRT+/– inoculated mice showed significant reduction of specific anti T. cruzi antibody levels. BALB/c mice were inoculated
with 56105 metacyclic trypomastigotes. Results are expressed as the ratio of the absorbance of each serum sample at 490-nm. Dotted lines: Cut-off
value adopted for positivity calculated as the mean of the values obtained for the negative controls (inoculated with PBS) plus three times the
standard deviation. Serum samples were taken at the intervals indicated. TcCRT+/– inoculated mice showed significant reduction of antibody levels
compared to those inoculated with wild type and TcCRT+ clones (p = 0.01 for both cases). Positive controls: serum from mice infected with the
virulent Tulahue´n T. cruzi strain.
doi:10.1371/journal.pntd.0002696.g001
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higher than in the non-immunized group (p = 0.0001). Mice
immunized with TcCRT+/– and wild type parasites showed, after
challenge, reduced levels of circulating parasites in peripheral
blood, ranging between 0–3 parasites per 100 microscopic fields
throughout follow-up, demonstrating the protection afforded by
immunization. Parasitemia curves between wild type and
TcCRT+/– immunized groups are not significantly different (p
= 0.22). These results showed that deletion of a TcCRT allele does
not modify the protective response induced by TCC wild type
parasites. In contrast, mice immunized with TcCRT+ did not
afford protection (Fig 3A). Non-immunized control mice presented
high parasitemia with peaks between days 13 and 16, at a time
when there was 50% mortality. As expected, these mice showed
high parasitemia before death, thus explaining the wide dispersion
of the data at that time (Fig 3A). In contrast, in the remaining
experimental groups no mortality was recorded. TcCRT+/–
immunized and boosted mice showed undetectable specific anti-T.
cruzi antibody levels (similar to those obtained in the non-
immunized, negative controls) compared to the levels found in
both wild type and TcCRT+ (p = 0.004) and clearly different from
those obtained from mice infected with Tulahue´n parasites (Fig
3B).
Autopsies were performed on mice 4 months after priming with
TCC TcCRT+/–; TcCRT+ or wild type trypomastigotes and 2
months after a virulent T. cruzi challenge. Non-immunized, wild
type and TcCRT+ mice presented severe inflammatory response
throughout the heart tissue, however, this response was extensively
reduced in TcCRT+/– immunized mice (p = 0.002) (Fig. 4A), thus
confirming the protective effect conferred by previous immuniza-
tion with these parasites. The same effect was observed in muscle
tissue: non immunized, wild type and TcCRT+ mice presented
moderate to slight cellular damage that was reduced in
TcCRT+/– immunized mice (p = 0.0007) (Fig. 4B).
Splenomegaly is a macroscopic manifestation of the expansion
of B- and T-lymphoid cell populations produced by the infection
of mice with T. cruzi [41]. Thus, the spleen index represents an
indirect effect of infection severity. Spleen index at day 60 post-
challenge was significantly decreased in TcCRT+/– and wild type
immunized mice compared to that in the non-immunized controls
(p = 0.02 for both cases). However, TcCRT+ immunized mice
presented no differences (p = 0.14) with non-immunized controls
(Fig. 4G).
Discussion
In a previous work, we have characterized a mutant cell line
that lacks a TcCRT allele (TcCRT+/–), with bases on the
attenuated TCC T. cruzi strain. We showed that TcCRT+/–
epimastigotes contained about 6-fold less TcCRT polypeptide
than wild type parasites. Moreover, they were significantly
susceptible to killing by the complement machinery and presented
a reduced in vitro propagation and differentiation rate. In addition,
we generated another clonal cell line that over-expresses TcCRT
(TcCRT+) and showed high resistance levels to complement
attack [35]. Furthermore, it was not possible to generate biallelic
TcCRT–/– null mutant clones, perhaps a reflection of the
essential character of the TcCRT protein for parasite survival.
TCC wild type infection is hardly detected in immunocompe-
tent animal models due to the attenuation of this strain. The use of
highly sensitive methods such as immunosupression regimens
followed by PCR and hemoculture is usually required. When
inoculated in Balb/c mice, and during a 6-month follow-up
period, mutant TcCRT+/– parasites were not detected by either
of these techniques, even after immunosupression (Table 1).
TcCRT is highly immunogenic in different animal species [42].
Most humans infected with T. cruzi possess anti-TcCRT antibodies
[43]. However, levels of specific antibodies in TcCRT+/–
inoculated mice were even more reduced as compared to mice
inoculated with wild type or TcCRT+ and, as described [27], with
the highly infective Tulahue´n strain (Fig. 1).
The increased virulence attenuation of TcCRT+/– in mice
could probably be related to increased complement susceptibility
Figure 2. TcCRT+/– mutant parasites are stable after prolonged infection in mice. (A) Schematic representation of the TcCRT genomic locus
in TcCRT+/– parasites (B) PCR analysis carried out from genomic DNA of TcCRT+/– and wild type parasites recovered from hemocultures of chronically
infected mice. Primers: Pair CRT1-CRT2 and H1-H2 amplify the TcCRT (1.2 KB) and HYG CDS (0.96 kb), respectively. Pair CRT7-H4 amplifies the 5’ UTR
of TcCRT together with a fragment of the HYG CDS (1.45 kb). Pair CRT93-H6 amplifies the 3’ UTR of TcCRT together with a fragment of the HYG CDS
(1.4 kb). The sizes of the fragments correspond to those predicted for the replacement of TcCRT by the HYG gene.
doi:10.1371/journal.pntd.0002696.g002
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and to the deposition of C1q on the parasite surface, configuring a
strategy called "apoptotic mimicry". In infective trypomastigotes,
TcCRT is translocated from the ER to the area of flagellum
emergence where it could hijack C1q resulting in an increased
affinity for host cells [32,33,44]. Previous reports affirm that the
C1q binding on the T. cruzi trypomastigote surface increases
parasite infectivity [45] and thus, any disruption of TcCRT/C1q
interaction may result in a reduction of infectivity both, in vitro and
Figure 3. Inoculation of TcCRT+/– mutant parasites protects mice against a virulent T. cruzi challenge. (A) Balb/c mice were primed and
boosted with metacyclic trypomastigotes TCC wild type, TcCRT+, TcCRT+/– or PBS. On day 120, all mice were challenged with 104 bloodstream forms
of a virulent T. cruzi TcVI isolate. Note the protection (p = 0.0001) in TcCRT+/– and wild type-preinoculated mice. (B) Dispersion diagrams of specific
anti-T. cruzi antibody levels elicited in either naive mice (non- immunized) and those immunized and boosted with 56105 metacyclic trypomastigotes
TcCRT+/–, wild type or TcCRT+ clone. The results are expressed as the ratio of the absorbance of each serum sample at 490-nm. Dotted lines: Cut-off
value adopted for positivity calculated as the mean of values obtained for the negative controls plus three standard deviations. Serum samples were
taken at day 30 post-priming. TcCRT+/– immunized mice showed undetectable antibody levels as compared to mice inoculated with wild type and
TcCRT+ clones (p = 0.006 for both cases). Data (mean 6 SD) presented are representative of three independent experiments (n = 6/group/
experiment).
doi:10.1371/journal.pntd.0002696.g003
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in vivo [33,34]. Furthermore, apoptotic mammalian cells express
surface ligands with high C1q affinities, among them, the
calreticulin orthologue. C1q-coating over apoptotic cells produces
pro-phagocytic ‘‘eat me’’ signals that promote clearance of
apoptotic bodies conducted by phagocytic cells [46,47]. One of
our laboratories [33], proposed that T. cruzi expressing TcCRT
mimic the ‘‘eat me’’ signals, promoting C1q coating, phagocytic
cell chemotaxis and increasing parasite infectivity in the early
stages of infection. In our work, the TcCRT allele deletion and
synthesis reduction [35], possibly generated a lower capacity to
capture C1 thereby inducing lower pro-phagocytic signals and
reduced infectivity of phagocytic cells in the early stages of
infection. In a negative feedback, the limited invasion of
phagocityc cells would help TcCRT+/– parasites to stay free,
for a longer period of time, and exposed to the complement lytic
action in the bloodstream system of the host. These properties may
have contributed to the important TcCRT+/– infectivity atten-
uation (Table 1).
In addition, antibodies aggregated to the T. cruzi surface
antigens (including the anti-TcCRT antibodies) through their Fc
regions have a high affinity for C1q [33]. Thus the apparent
paradox that C1q-fixing antibodies, rather than preventing
parasite replication, contribute to increase their infectivity, is
explained. Thus, pretreatment with anti-TcCRT (Fab’)2 fragments
(which lack the Fc fragment of C1q binding) produces the
disruption of TcCRT/C1q with serious negative impact on the in
vivo e in vitro infectivity [33]. As expected, the TcCRT+/–
attenuated line did not produce detectable specific anti-T. cruzi
antibodies (Fig.1) probably causing a limited C1q deposit on the
parasite surface which, in turn, would contribute to diminish
phagocytic signals and hence parasite infectivity. In contrast, mice
inoculated with TcCRT+ and wild type showed an increased level
in antibody titers compared to TcCRT+/–, which would generate
a denser C1q coating. This phenomenon may explain the
divergences in infectivity of TcCRT+/–, TcCRT+ and wild type
parasites.
We were unable to recover infecting parasites from immuno-
competent mice by hemoculture. However, we could detect
parasite DNA by PCR in those mice infected with TCC wild type
and TcCRT+ parasites (Table 1). This is probably a consequence
of both a lower density of circulating parasites and a greater PCR
sensitivity for detection of T. cruzi in mouse blood (X 20) as
compared with hemoculture [27].
In agreement with our hypothesis, mice inoculated with
TcCRT+ and wild type parasites infected a high percentage of
mice, although without detectable differences between these
groups.
It is unclear whether TcCRT+/– parasites did infect. However,
the possibility that infection occurs is favored by the fact that an
adaptive protective status was verified when the animals were
challenged 4 months after a primary infection. Since only
marginal antibody levels were occasionally detected, protection
maybe cellular rather than humoral, issues now under investiga-
tion in our laboratories.
Using immunedeficient nu/nu mice, infections caused by the
three parasite populations could be detected in a high proportion
of mice and even in hemocultures (Table 1). These results confirm
previous studies from our laboratory, showing that the TCC wild
type strain infects immature or immunocompromised animals
[24,48]. These results suggest that although TcCRT+/– infectivity
is attenuated, the suppression of host immunity allows the
replication and persistence of these parasites in animals. A similar
behavior was observed in the dhfr-ts (dihydrofolate reductase-
thymidylate synthase) single mutant, also developed on the TCC
T. cruzi strain. This mutant showed a reduced infectivity in
immunocompetent mice and as in this work, no mutant parasites
could be recovered from hemocultures [20].
The virulence reduction in genetically modified parasites in
mice models has previously been reported for genes Tc52 [49] and
oligopeptidase B [50]. In our laboratory, this phenomenon was
observed working with mutant gp72 genes [19], cub (calmodulin-
ubiquitin) [17], lyt1 [18] and dhfr-ts [20].
We have extensively studied the TCC T. cruzi strain as a live
attenuated experimental vaccine [28,29,51]. The molecular basis
of the TCC attenuation is unknown. Thus, we incorporated a
rational attenuation mechanism (targeted gene deletion) as a safety
device to eliminate the possibility of reversion to a virulent
phenotype. In this regard, we tried to rule out the possible
reversion of the TcCRT+/– genetic modifications during the
chronic stage of the disease in mice. We recovered TcCRT+/–
parasites from nude mice at day 90 p.i. (Table 1) and detected
sequences corresponding to the TcCRT locus engineering. Thus,
the TcCRT+/– mutation is genetically stable in chronically
infected mice and there is no reversion to the TCC wild type
genotype (Fig.2). Furthermore, the same experiment ruled out
strain cross contamination during handling in the laboratory.
Moreover, we tested whether the TcCRT+/– attenuation
affects the protective capacity of the TCC wild type parasites
against a virulent challenge. Our results suggest that the deletion of
one TcCRT allele did not change the already reported
immunoprotection induced by TCC wild type parasites [28].
Using TcCRT+/– immunized mice we did not obtain, after a
virulent challenge, a sterilizing protective response, although, we
achieved low parasite density, mortality (Fig.3A) and a significantly
reduced tissue inflammatory response (Fig.4A–F) and spleen index
(Fig.4G). Infection with the parental TCC clone has been shown
to be protective, in spite of the fact that it generates inflammatory
foci in cardiac tissue [23]. When we inactivated one of the TcCRT
Figure 4. TcCRT+/– immunization decreases tissue inflamma-
tory response and spleen indexes in challenged mice. Autopsies
were performed on mice 4 months post-priming and 2 months after
virulent challenge. Dispersion diagrams of histopathological alterations
in hearth muscle (A) and skeletal tissue (B). The inflammatory responses
were graded as absent (–), slight (+), moderate (++), and severe (+++).
Each dot represents a mouse. Representative images of H&E staining
(blue: nuclear, pink: muscle/cytoplasm/keratin) of heart tissue (C and D)
and skeletal muscle sections (E and F) from non-immunized and
TcCRT+/– mice respectively (magnification, 25X). Li, Lymphocytic
infiltrates. (G) Spleen indexes on day 60 post-challenge. Mice inoculated
with TcCRT+/– parasites present lower spleen indexes compared with
non-immunized controls (p = 0.02) and TcCRT+ parasites (p = 0.004).
doi:10.1371/journal.pntd.0002696.g004
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alleles, a significant decrease in local inflammation is recorded,
perhaps a reflection of an impaired virulence. Certainly, the most
important fact was that the protective response was achieved at the
cost of a possible primary infection with attenuated TcCRT+/–
parasites which could not be detected by our most sensitive
methods during a six month follow-up and even after immuno-
suppression of the infected mice (Table 1). It is crucial for
vaccinating parasites not to persist in the organism and to
discontinue the transmission cycle in peridomestic animals from
endemic areas. This could impact over the Chagas disease
infection incidence.
In a previous work [33], mice immunization with TcCRT
induced the generation of specific anti-TcCRT antibodies
resulting in increased parasitemia of the T. cruzi-challenged mice.
Most likely, as mentioned above, immunization with TcCRT
induces C1q binding anti-TcCRT antibodies thus increasing the
parasite infectivity in the challenged animals. According to this
hypothesis, TcCRT+ immunized mice showed higher levels of
specific anti-T. cruzi antibodies (Fig 3B) inducing an elevated
parasitemia after challenge (Fig 3A). On the contrary, the
TcCRT+/– attenuated line did not produce detectable antibodies
(Fig 3B) or parasitemia post-challenge (Fig 3A).
Wild type TCC parasites are not detectable by direct blood
examination, however, they could be detected by PCR in
cyclophosphamide treated chronically infected mice (Table 1) or
after hemoculture recovery. In this regard, the attenuated
biological behavior of the TcCRT+/– mutants is interesting
because if employed as live immunogens, an eventual (natural or
induced) immunosuppression of the host should not produce the
reactivation of the vaccinating parasites.
Inoculation and eventual infection with TcCRT+/– parasites
did not induce detectable antibodies levels (Fig.1 and 3B).
However, protection from T. cruzi infection is considered at
present to be mediated primarily by cytotoxic T cells [52] and not
by antibodies.
In summary, our results show that TcCRT+/– clones were
restricted in two important properties conferred by TcCRT and
indirectly by C1q: the ability to evade the host immune response,
and their virulence status. Therefore, deletion of one copy of the
TcCRT gene in the attenuated TCC strain resulted in the
generation of a safe and irreversibly gene-deleted live attenuated
parasite with high experimental immunoprotective properties.
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